High-density lipoprotein cholesterol

There are 727 papers on high-density lipoprotein cholesterol in aging research: 107 trials and 527 observational studies in people, 7 in animals, 81 reviews. The newest story, Nov 9, 2026: “Clinical obesity has genetic links beyond body mass index”.

Biomarker

727 papers study it1,119 more mention it204 findings

123 new papers in 30 daysSee all 1,846 papers on high-density lipoprotein cholesterol

“Changes in peak oxygen uptake were associated with changes in HDL-C in both men and women”
The Long-term Effect of Different Exercise Intensities on High-Density Lipoprotein Cholesterol in Older Men and Women Using the Per Protocol Approach: The Generation 100 StudyMayo Clinic proceedings. Innovations, quality & outcomes2021doi:10.1016/j.mayocpiqo.2021.07.002
  • Human trial107
  • Humans527
  • Animals7
  • In silico4

Interventions

52

Exercise

upin humans4

4 studies
  1. Exercise increases high-density lipoprotein cholesterol in humans (Hedges’ g = 0.28).

    “while increasing HDL-C (Hedges’ g = 0.28, p = 0.009”

    Human trial6 to 52 weeksn = 2,578

    Effects of exercise intervention on glucose and lipid metabolism in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease: a three-level meta-analysis

    Frontiers in nutrition

  2. Exercise increases high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease (Hedges' g = 0.28, p = 0.009).

    “and increased HDL-C (Hedges' g = 0.28, p = 0.009).”

    Human trialin patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease

    Effects of exercise intervention on glucose and lipid metabolism in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease: a three-level meta-analysis

    Frontiers in nutrition

  3. Exercise increases high-density lipoprotein cholesterol in humans.

    “and an increase in HDL cholesterol (p = 0.007).”

    Human trial12 weeksfemalesn = 29

    Effects of a 12-Week Supervised Exercise Program on Quality of Life, Functional Capacity, and Biological Parameters in Women with Breast Cancer: A Prospective Pilot Program

    Journal of clinical medicine

  4. Exercise increases high-density lipoprotein cholesterol in humans.

    “Exercise significantly increased aerobic and muscle fitness, lean mass, and high-density lipoprotein cholesterol and reduced total and abdominal fat.”

    Human trial6 months

    Exercise and risk factors associated with metabolic syndrome in older adults

    American journal of preventive medicine

  5. Exercise increases high-density lipoprotein cholesterol in humans (SMD 0.22 (95% CI 0.09-0.35), P = .001).

    “exercise had a significant effect on HDL cholesterol levels (standard mean difference [95% confidence interval] = 0.22 [0.09-0.35], Z = 3.28, P = .001, I2 = 54%)”

    Review

    Effects of exercise on high-density lipoprotein levels in middle-aged and older individuals: A systematic review and meta-analysis

    Medicine

More on Exercise

Resveratrol

no changein humans3upin humans1

4 studies
  1. Resveratrol increases high-density lipoprotein cholesterol in humans (type 2 diabetes mellitus) (3.62±8.75 mg/dL, p=0.01).

    “increased high density lipoprotein (3.62±8.75 mg/dL, p=0.01) levels compared with placebo”

    Human trialtype 2 diabetes mellitusmicronized trans-resveratrol1000 mg/day8 weeksn = 71

    The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial

    Phytotherapy research : PTR

  2. Resveratrol showed no clear effect on high-density lipoprotein cholesterol in humans (new diagnosis of dyslipidemia).

    “without significant statistical differences for high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels”

    Human trialnew diagnosis of dyslipidemia100 mg/d2 mon = 71

    Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial

    Nutrition (Burbank, Los Angeles County, Calif.)

  3. Resveratrol showed no clear effect on high-density lipoprotein cholesterol in humans (SMD = 0.00, 95 % CI: -0.04, 0.05; p =0.92).

    “but not high-density lipoprotein cholesterol (HDL-c) (SMD = 0.00, 95 % CI: -0.04, 0.05; p =0.92)”

    Review

    Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis

    Prostaglandins & other lipid mediators

  4. Resveratrol showed no clear effect on high-density lipoprotein cholesterol in humans (WMD: -0.01 mmol/l, 95% CI: -0.04, 0.02).

    “high density lipoprotein (HDL-C) (WMD: -0.01 mmol/l, 95% CI: -0.04, 0.02; P = .269, I2 = 88.6%)”

    Review

    Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials

    Pharmacological research

More on Resveratrol

Curcumin

upin humans3no changein humans1

4 studies
  1. Curcumin showed no clear effect on high-density lipoprotein cholesterol in humans (nonalcoholic fatty liver disease).

    “whereas serum levels of high-density lipoprotein cholesterol and glucose control parameters remained unaltered.”

    Human trialnonalcoholic fatty liver disease1000 mg/d8 weeksn = 87

    Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

    Journal of cardiovascular pharmacology

  2. Curcumin increases high-density lipoprotein cholesterol in humans (patients with metabolic syndrome) (from 40.96 ± 8.59 to 43.76 ± 2.79 mg/dL (p < 0.05)).

    “the level of high-density lipoprotein cholesterol (HDL-C) significantly increased from 40.96 ± 8.59 to 43.76 ± 2.79 mg/dL (p < 0.05)”

    Human trialpatients with metabolic syndromecapsule1890 mg/day12 weeksn = 33

    Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial

    Phytotherapy research : PTR

  3. Curcumin increases high-density lipoprotein cholesterol in humans (ES = 1.34 mg/dl, 95% CI: 0.37 to 2.31).

    “Curcumin intake significantly increased high-density lipoprotein cholesterol (HDL-C) levels (ES: 1.34 mg/dl, 95% CI: 0.37, 2.31, p = 0.007”

    Review

    Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  4. Curcumin increases high-density lipoprotein cholesterol in patients with metabolic syndrome (p = 0.003).

    “The results showed significant improvement of fasting blood glucose (p = 0.01), triglycerides (p < 0.001), high-density lipoprotein cholesterol (p = 0.003), and diastolic blood pressure (p = 0.007) levels.”

    Reviewin patients with metabolic syndrome

    Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials

    Phytotherapy research : PTR

More on Curcumin

High-intensity interval training

upin humans2no changein humans1downin humans1

3 studies
  1. High-intensity interval training showed no clear effect on high-density lipoprotein cholesterol in humans.

    “No effect of exercise intensity on HDL-C was seen in women.”

    Human trial5 yearsfemales

    The Long-term Effect of Different Exercise Intensities on High-Density Lipoprotein Cholesterol in Older Men and Women Using the Per Protocol Approach: The Generation 100 Study

    Mayo Clinic proceedings. Innovations, quality & outcomes

  2. High-intensity interval training prevents high-density lipoprotein cholesterol in humans (-1.2% vs -6.9% and -7.8%).

    “Men in HIIT had a smaller reduction in HDL-C (-1.2%) than men in CON (-6.9%) and MICT (-7.8%) after 5 years”

    Human trial5 yearsmales

    The Long-term Effect of Different Exercise Intensities on High-Density Lipoprotein Cholesterol in Older Men and Women Using the Per Protocol Approach: The Generation 100 Study

    Mayo Clinic proceedings. Innovations, quality & outcomes

  3. High-intensity interval training increases high-density lipoprotein cholesterol in humans (polycystic ovary syndrome) (MD = 0.05 mmol/l, 95% CrI 0.01 to 0.10).

    “high-intensity interval training (HIIT) ranked best for improving high-density lipoprotein cholesterol (No = 117, k = 6; MD = 0.05 mmol/l, 0.01 to 0.10)”

    Reviewpolycystic ovary syndromefemalesn = 117

    Lifestyle interventions for cardiometabolic health in women with polycystic ovary syndrome: a systematic review and network meta-analysis

    Human reproduction update

  4. High-intensity interval training increases high-density lipoprotein cholesterol in humans (MD: 0.04mmol L− 1, P = 0.0007).

    “high-density lipoprotein levels (HDL) [MD:0.04mmol L− 1, P = 0.0007]”

    Review

    Effects of high-intensity interval training on physical morphology, cardiopulmonary function, and metabolic indicators in older adults: A PRISMA-based systematic review and meta-analysis

    Research SquarePreprint

More on High-intensity interval training

Testosterone

downin humans2upin humans1

3 studies
  1. Testosterone decreases high-density lipoprotein cholesterol in humans (-0.1 mmol/L).

    “decrease in high-density lipoprotein cholesterol (-0.1 mmol/L) at 12 months in the testosterone group as compared to the placebo group (p = 0.026).”

    Human trialtestosterone undecanoate80 mg twice daily12 monthsmalesn = 76

    Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Testosterone increases high-density lipoprotein cholesterol in humans (developing countries) (MD 2.79 (95% CI: 0.73 to 4.86)).

    “TST increased HDL-C level in developing countries compared with the control group (MD = 2.79; 95% CI: 0.73 to 4.86; I2 = 0%; p = 0.008)”

    Reviewdeveloping countriesmales

    Effects of testosterone supplementation therapy on lipid metabolism in hypogonadal men with T2DM: a meta-analysis of randomized controlled trials

    Andrology

  3. Testosterone decreases high-density lipoprotein cholesterol in humans (WMD -0.49 mg/dl, 95% CI -0.85 to -0.13).

    “a decrease in high-density lipoprotein cholesterol (WMD, -0.49 mg/dl; 95% CI, -0.85 to -0.13)”

    Reviewmales

    Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis

    The Journal of clinical endocrinology and metabolism

More on Testosterone

Dehydroepiandrosterone

downin humans2no changein humans1−20%

3 studies
  1. Dehydroepiandrosterone decreases high-density lipoprotein cholesterol in humans (hypoadrenal) (2.0 vs. -6.0, P = 0.006).

    “high-density lipoprotein (HDL) levels (2.0 vs. -6.0, P = 0.006)”

    Human trialhypoadrenaloralplasma50 mg/d3 monthsfemalesn = 33

    Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women

    The Journal of clinical endocrinology and metabolism

  2. Dehydroepiandrosterone showed no clear effect on high-density lipoprotein cholesterol in humans (perimenopausal women) (-10.1% HDL, -18.1% Lp(a) vs placebo NS).

    “Women receiving DHEA had a 10.1% (95% CI -15.0, -5.1) decline in high-density lipoprotein and an 18.1% (95% CI -32.2, -3.9) decline in Lp(a) from baseline, but these declines did not significantly differ from women who received placebo.”

    Human trialperimenopausal womenoral50 mg/day3 monthsfemales

    The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life

    The Journal of clinical endocrinology and metabolism

  3. Dehydroepiandrosterone decreases high-density lipoprotein cholesterol in humans (-20.0%).

    “20.0% (P less than 0.05) in high density lipoprotein noted within the first week of DHEA administration persisted for the 28-day period”

    Human trialoral1600 mg/day28 daysfemalesn = 6

    The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women

    The Journal of clinical endocrinology and metabolism

More on Dehydroepiandrosterone

Resistance training

upin humans1no changein humans1

2 studies
  1. Resistance training increases high-density lipoprotein cholesterol in humans (postmenopausal women with abdominal obesity) (+3.34 mg/dL, p = 0.016).

    “ST showing an increase of 3.34 mg/dL, (p = 0.016)”

    Human trialpostmenopausal women with abdominal obesity12 weeksfemales

    Effect of high intensity interval Nordic walking and strength training on selected biomarkers of metabolic syndrome in postmenopausal women with abdominal obesity: a quasi-experimental studies

    Frontiers in physiology

  2. Resistance training showed no clear effect on high-density lipoprotein cholesterol in humans.

    “resistance and stretching exercises had no significant effect on HDL levels”

    Review

    Effects of exercise on high-density lipoprotein levels in middle-aged and older individuals: A systematic review and meta-analysis

    Medicine

More on Resistance training

Selenium

downin humans1upin humans1

2 studies
  1. Selenium decreases high-density lipoprotein cholesterol in humans.

    “however, high-density lipoprotein cholesterol significantly decreased.”

    Human trialtablets120 μg/day30 daysn = 40

    Comprehensive Insights into the Health Effects of Selenium Exposure and Supplementation Among the Chinese Community Middle-Aged and Elderly: a Combined Retrospective Cohort Study and Intervention Study

    Biological trace element research

  2. Selenium is linked with higher high-density lipoprotein cholesterol in humans (subjects meeting MetS criteria) (p=0.007).

    “Higher selenium concentrations increased the odds of higher HDL levels in the group of subjects meeting the MetS criteria.”

    Humanssubjects meeting MetS criteriabloodfemalesn = 390

    Selenium as a predictor of metabolic syndrome in middle age women

    Aging

More on Selenium

Fish oil

upin humans2

2 studies
  1. Fish oil increases high-density lipoprotein cholesterol in humans (endstage renal disease).

    “High-density lipoprotein cholesterol levels significantly decreased in the control group, and increased in the fish-oil group, at 6 months”

    Human trialendstage renal diseaseconcentratesix 1-g soft-gel capsules each day6 monthsn = 87

    Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  2. Fish oil increases high-density lipoprotein cholesterol in humans (stable claudication).

    “high-density cholesterol increased and triglycerides decreased”

    Human trialstable claudicationsix capsules (1.8 g EPA and 1.2 g DHA)4 monthsn = 32

    Fish oil supplementation in patients with stable claudication

    American journal of surgery

More on Fish oil

Coffea arabica

upin humans1

1 study
  1. Coffea arabica increases high-density lipoprotein cholesterol in humans.

    “CPE product significantly reduced TC (p = 0.005), LDL-C (p < 0.0001), and TG level (p < 0.0001) but increased HDL-C level (p < 0.0001) compared to the placebo group at week 24.”

    Human trial24 weeks

    Potential lipid-lowering effects of Coffea arabica pulp extract product in hyperlipidemia-obese subjects: a randomized double-blind placebo-controlled trial

    Frontiers in nutrition

  2. Coffea arabica increases high-density lipoprotein cholesterol in humans (hyperlipidemia and obesity) (+7.1% vs. -5.0%, p < 0.0001).

    “HDL-C increased in the CPE group but decreased in the placebo group after adjustment (+7.1% vs. -5.0%, p < 0.0001).”

    Human trialhyperlipidemia and obesityproductbloodtwice daily24 weeksn = 79

    Potential lipid-lowering effects of Coffea arabica pulp extract product in hyperlipidemia-obese subjects: a randomized double-blind placebo-controlled trial

    Frontiers in nutrition

More on Coffea arabica

Exercise snacks

upin humans1

1 study
  1. Exercise snacks increase high-density lipoprotein cholesterol in humans (compared to traditional exercise).

    “Between-group comparisons revealed a significantly greater reduction in TG levels in TEG compared to ESG (p < 0.05), while the increase in HDL-C was significantly greater in ESG than in TEG (p < 0.05).”

    Human trialcompared to traditional exercise12-weekmalesn = 34

    Effects of Exercise Snack Program on Quality of Life, Cardiorespiratory Fitness, and Metabolic Flexibility in Elderly Cancer Survivors: A Preliminary Study

    Life (Basel, Switzerland)

  2. Exercise snacks increase high-density lipoprotein cholesterol in humans (cancer survivors) (p < 0.05).

    “Quality-of-life vitality, social functioning, cardiorespiratory fitness VO2 peak, and high-density lipoprotein cholesterol were improved more in ESG than in TEG (p < 0.05).”

    Human trialcancer survivors12 weeks

    Effects of Exercise Snack Program on Quality of Life, Cardiorespiratory Fitness, and Metabolic Flexibility in Elderly Cancer Survivors: A Preliminary Study

    Life (Basel, Switzerland)

More on Exercise snacks

Multidomain intervention

upin humans1upin reviews1

1 study
  1. Multidomain intervention increases high-density lipoprotein cholesterol in humans (+6.65 mg/dL, p < 0.001).

    “Cardiometabolic improvements included increased HDL-C (+6.65 mg/dL, p < 0.001) and decreased triglycerides (-16.07 mg/dL, p = 0.025) at 12 months in GEE models.”

    Human trial12 months

    Enhancing Neurocognitive Health via Activity, Nutrition and Cognitive Exercise (ENHANCE): A Randomized Controlled Trial

    Journal of cachexia, sarcopenia and muscle

  2. Multidomain intervention increases high-density lipoprotein cholesterol (+6.65 mg/dL).

    “Cardiometabolic outcomes showed improvement in the intervention group, with increased HDL‐C (+6.65 mg/dL, p < 0.001) and decreased triglycerides (−16.07 mg/dL, p = 0.025) at 12th month compared with that at the 6th month.”

    Review12 monthsn = 102

    Enhancing Neurocognitive Health via Activity, Nutrition and Cognitive Exercise (ENHANCE): A Randomized Controlled Trial

    Journal of cachexia, sarcopenia and muscle

More on Multidomain intervention

Caulerpa racemosa

upin humans1

1 study
  1. Caulerpa racemosa increases high-density lipoprotein cholesterol in humans (compared with placebo).

    “There was also a significant increase (p = 0.000) in PGC-1α and HDL, respectively, in the sea grape extract group when compared with the placebo group.”

    Human trialcompared with placebo4 weeksn = 69

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

  2. Caulerpa racemosa increases high-density lipoprotein cholesterol in humans (compared with Group A) (p = 0.000).

    “PGC-1α and high-density lipoprotein (HDL) increased significantly (p = 0.000), in Group B when compared with Group A.”

    Human trialcompared with Group A4-week

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

More on Caulerpa racemosa

Fasting-mimicking diet

upin humans1

1 study
  1. Fasting-mimicking diet increases high-density lipoprotein cholesterol in humans (2.28 ± 0.50 vs 1.42 ± 0.27 mmol/L).

    “HDL-C was 2.28 ± 0.50 and 1.42 ± 0.27 mmol/L, respectively, showing significant statistical intergroup differences (all P < 0.05; see ).”

    Human trial4-monthn = 100

    Effects of Fasting-Mimicking Diet and Specific Meal Replacement Foods on Blood Glucose Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

    Oxidative medicine and cellular longevity

  2. Fasting-mimicking diet increases high-density lipoprotein cholesterol in humans (type 2 diabetes).

    “and high-density lipoprotein levels were all higher than the control group (all P < 0.05)”

    Human trialtype 2 diabetes4 monthsn = 100

    Effects of Fasting-Mimicking Diet and Specific Meal Replacement Foods on Blood Glucose Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

    Oxidative medicine and cellular longevity

More on Fasting-mimicking diet

SGLT2 inhibitors

upin humans1

1 study
  1. SGLT2 inhibitors increase high-density lipoprotein cholesterol in humans (add-on to metformin in type 2 diabetes) (+5.73 mg/dl).

    “and an increase in high-density lipoprotein cholesterol (+5.73 mg/dl; P<0.01)”

    Human trialadd-on to metformin in type 2 diabetes12 months

    12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

    Clinical pharmacology : advances and applications

  2. SGLT2 inhibitors increase high-density lipoprotein cholesterol in humans (+5.73 mg/dL).

    “In the intra-group analysis, we found statistically significant differences (pre–post) in the SGLT2-I group in terms of body weight (−1.95 kg; P<0.05), BMI (−0.69 kg/m2; P<0.05), and higher HDL cholesterol (+5.73 mg/dL; P<0.01).”

    Human trial52 weeks

    12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

    Clinical pharmacology : advances and applications

More on SGLT2 inhibitors

All 52

Effects

13

Mortality

no changein humans2HR 1–1.02

2 studies
  1. High-density lipoprotein cholesterol was not clearly linked with mortality in humans after adjustment (HR 1.00, 95% CI 1.00-1.01, p = 0.482).

    “no significant association was observed between HDL-C and all-cause mortality after adjustment (HR 1.00, 95% CI 1.00-1.01, p = 0.482).”

    Humansafter adjustment

    Association of HDL-C Levels with Stroke and All-cause Mortality: A Prospective Cohort Study from the CHARLS

    Brain and behavior

  2. High-density lipoprotein cholesterol was not clearly linked with mortality in humans (compared with medium-high-level group (1.55-1.80 mmol/L)) (HR 1.02 (0.95-1.11)).

    “and 1.02 (0.95-1.11) (P>0.05)”

    Humanscompared with medium-high-level group (1.55-1.80 mmol/L)<1.30 mmol/L

    Association between high-density lipoprotein cholesterol level and cardiovascular disease and all-cause mortality in the elderly population

    Zhonghua xin xue guan bing za zhi

Epigenetic age

upin humans1downin humans1

1 study
  1. High-density lipoprotein cholesterol is linked with higher epigenetic age in humans (HDL-C above 78 mg/dL) (β = 0.07, 95% CI: 0.03-0.12).

    “beyond this point, further increases were associated with aging acceleration (β = 0.07, 95% CI: 0.03-0.12)”

    HumansHDL-C above 78 mg/dL

    U-shaped association between HDL-C and epigenetic age acceleration: A cross-sectional analysis from NHANES 1999-2002

    Medicine

  2. High-density lipoprotein cholesterol is linked with lower epigenetic age in humans (HDL-C below 78 mg/dL) (β = -0.03, 95% CI: -0.04 to -0.01).

    “Below the threshold, incremental HDL-C elevations correlated with aging deceleration (β = -0.03, 95% CI: -0.04 to -0.01)”

    HumansHDL-C below 78 mg/dL

    U-shaped association between HDL-C and epigenetic age acceleration: A cross-sectional analysis from NHANES 1999-2002

    Medicine

More on Epigenetic age

Atherosclerotic cardiovascular disease

downin humans1HR 0.95

1 study
  1. High-density lipoprotein cholesterol is linked with lower atherosclerotic cardiovascular disease in humans (apoB-HDL-C interaction test) (HR 0.95, 95% CI 0.93-0.96).

    “The apoB-HDL-C interaction was significant: HR 0.95 (95% CI: 0.93-0.96; p < 0.001), consistent across sexes.”

    HumansapoB-HDL-C interaction test10 yearsn = 293,872

    Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank

    European journal of preventive cardiology

More on Atherosclerotic cardiovascular disease

Cardiovascular disease

no changein humans1HR 0.64

1 study
  1. High-density lipoprotein cholesterol was not clearly linked with cardiovascular disease in humans (CAVI ≥ 9) (HR 0.64, 95% CI 0.33-1.24, p = 0.640).

    “In the group with CAVI > 9, the risk of CVEs in patients with HDL-C < 40 mg/dL was not significantly different from that in those with HDL-C > 40 mg/dL (HR 0.64, 95% CI 0.33-1.24, p = 0.640).”

    HumansCAVI ≥ 9< 40 mg/dLmedian follow-up of 5.0 yearsn = 2,068

    Predictive value of high-density lipoprotein cholesterol and the cardio-ankle vascular index on cardiovascular outcomes in subjects with cardiovascular risks: the COUPLING Study

    Hypertension research : official journal of the Japanese Society of Hypertension

More on Cardiovascular disease

Type 2 diabetes

mediatesin humans1

1 study
  1. High-density lipoprotein cholesterol is linked with type 2 diabetes in humans (between MQI and diabetes).

    “Mediation analysis identified that HDL and BMI serve as mediators between MQI and diabetes.”

    Humansbetween MQI and diabetesn = 4,088

    Protector role of muscle quality against diabetes in non-elderly U.S. adults

    Journal of diabetes and metabolic disorders

More on Type 2 diabetes

Squamous cervical cancer

no changein humans1OR 1.05

1 study
  1. High-density lipoprotein cholesterol was not clearly linked with squamous cervical cancer in humans (OR: 1.050; 95% CI: 0.616-1.790; p = 0.857).

    “HDL-C (OR: 1.050; 95% CI: 0.616-1.790; p = 0.857) and SCC”

    Humans

    Investigating the causal association between plasma lipids and the risk of squamous cervical cancer: A two-sample mendelian randomization study

    Journal of medical biochemistry

More on Squamous cervical cancer

Cognitive dysfunction

no changein humans1

1 study
  1. High-density lipoprotein cholesterol was not clearly linked with cognitive dysfunction in humans.

    “whereas TC, LDL-C, and HDL-C showed no significant associations (all P>0.05)”

    Humans

    Analysis of the correlation between blood lipid levels and cognitive dysfunction in elderly people aged 65 and above

    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

More on Cognitive dysfunction

Low muscle mass

no changein humans1

1 study
  1. High-density lipoprotein cholesterol was not clearly linked with low muscle mass in humans (P>0.05).

    “whereas no significant difference was found in the female subgroup (P>0.05).”

    Humansfemales

    Associations between high-density lipoprotein cholesterol levels and computed tomography-defined low muscle mass in older adults and sex-related differences

    Frontiers in endocrinology

Grip strength

downin humans1HR 1.23

1 study
  1. High-density lipoprotein cholesterol is linked with worse grip strength in humans (compared to reference group (40-60 mg/dl)) (HR 1.23 95% CI 1.00-1.51).

    “older adults with very high HDL-C level (>70 mg/dl) had a significantly higher risk of developing sarcopenia (HR 1.69, 95% CI 1.28-2.23) and low grip strength (HR 1.23 95% CI 1.00-1.51).”

    Humanscompared to reference group (40-60 mg/dl)>70 mg/dlaverage 3.7-year follow-upn = 4,031

    High-density lipoprotein cholesterol level and risk of muscle strength decline and sarcopenia in older adults

    Clinical nutrition (Edinburgh, Scotland)

Cognitive function

mediatesin humans1

1 study
  1. High-density lipoprotein cholesterol is linked with cognitive function in humans (tooth numbers and four cognitive tests) (2.11% to 5.24% of the total effect).

    “mediated 2.11% to 5.24% of the total effect between tooth numbers and cognitive function.”

    Humanstooth numbers and four cognitive testsn = 1,124

    The association between tooth loss and cognitive decline in the aged population: The mediating role of HDL-cholesterol

    Journal of dentistry

All 13

Upstream

2

Relative grip strength

upin humans1

1 study
  1. Relative grip strength is linked with higher high-density lipoprotein cholesterol in humans (β = 6.70, P < 0.001).

    “and higher HDL-C (β = 6.70, P < 0.001)”

    Humansn = 1,015

    Relationship Between Relative Grip Strength and Serum Total Cholesterol, High-Density Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Triglyceride Levels in Korean Middle-Aged or Older Adults: A Panel Regression Model

    Metabolic syndrome and related disorders

More on Relative grip strength

Telomere length

upin humans1

1 study
  1. Telomere length is linked with higher high-density lipoprotein cholesterol in humans (P = .013).

    “Mean serum high-density lipoprotein cholesterol concentrations significantly increased across increasing TL quarters ( P = .013)”

    Humansmalesn = 4,123

    Telomere Length Is Associated With Cardiometabolic Factors in US Adults

    Angiology

More on Telomere length

Associations

78

Mortality

downin humans3mixedin humans3HR 0.637–1.46

6 studies
  1. High-density lipoprotein cholesterol is linked with a lower risk of mortality in humans (HR=0.72, 95% CI: 0.57-0.92).

    “individuals in the second (37.9-45.8 mg/dL) and third (45.8-96.2 mg/dL) tertiles of HDL-C had a significantly lower risk of ACM compared with the lowest tertile”

    Humans37.9-45.8 mg/dL vs ≤37.9 mg/dL10 yearsn = 9,704

    Association of Serum Lipids with 10-Year CVD and All-Cause Mortality in Iranian Adults: A Prospective Cohort Study

    Archives of Iranian medicine

  2. High-density lipoprotein cholesterol predicts mortality in humans (Wald = 4.27, p = .039).

    “high density lipoprotein cholesterol levels (Wald = 4.27, p = .039)”

    Humansn = 901

    Beyond biology: Physical and mental health predictors of mortality in the sydney memory and ageing study

    Journal of psychiatric research

  3. High-density lipoprotein cholesterol is linked with a lower risk of mortality in humans after adjusting for confounders (HR = 0.637, 95% CI: 0.501-0.810).

    “the higher level of HDL-C (HR = 0.637, 95% CI: 0.501-0.810) were associated with lower risk of all-cause death”

    Humansafter adjusting for confoundersn = 4,499

    Cholesterol paradox in the community-living old adults: is higher better?

    Journal of geriatric cardiology : JGC

  4. High-density lipoprotein cholesterol is associated with mortality in humans (compared with medium-high-level group (1.55-1.80 mmol/L)) (HR 1.07 (1.00-1.16)).

    “marginal significant association with all-cause mortality, the HR (95%CI) was 1.07 (1.00-1.16)”

    Humanscompared with medium-high-level group (1.55-1.80 mmol/L)≥1.81 mmol/L

    Association between high-density lipoprotein cholesterol level and cardiovascular disease and all-cause mortality in the elderly population

    Zhonghua xin xue guan bing za zhi

  5. High-density lipoprotein cholesterol is associated with mortality in humans (adjusted for confounders) (HR 1.46 (1.09-1.95) for lowest, 1.45 (1.07-1.96) for highest quintile).

    “A U-shape relationship was found between HDL-C level and the mortality risk.”

    Humansadjusted for confounders10 yearsn = 3,239

    Low and High-Density Lipoprotein Cholesterol and 10-Year Mortality in Community-Dwelling Older Adults: The Shanghai Aging Study

    Frontiers in medicine

  6. High-density lipoprotein cholesterol is linked with a lower risk of mortality in humans (arterial hypertension).

    “The AIP was positively associated, while HDL concentration was negatively associated with the risk of all-cause death adjusted for age, smoking habits, statin use, history of diabetes mellitus, myocardial infarction, stroke and peripheral artery occlusive disease (PAOD) in elderly women but not in men.”

    Humansarterial hypertension10 yearsfemalesn = 247

    Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women : A 10-year follow-up

    Wiener klinische Wochenschrift

Cognitive function

upin humans4downin humans1

5 studies
  1. High-density lipoprotein cholesterol is associated with cognitive function in patients receiving maintenance hemodialysis (β = 0.06, 95% CI 0.03-0.10, P < 0.001).

    “higher serum HDL-C levels were independently associated with higher MoCA scores (fully adjusted model: β = 0.06; 95% confidence interval, 0.03-0.10; P < 0.001)”

    Humansin patients receiving maintenance hemodialysisserumn = 265

    High-density lipoprotein cholesterol and cognitive function in patients undergoing hemodialysis

    Clinical and experimental nephrology

  2. High-density lipoprotein cholesterol is associated with cognitive function in humans (below 67.43 mg/dL) (β = +0.08 (95% CI, 0.06-0.11) per 1-SD higher HDL-C).

    “Below the threshold, a 1-SD higher HDL-C was associated with a 0.08-SD higher cognitive score (β = +0.08; 95% CI, 0.06-0.11; p < 0.001)”

    Humansbelow 67.43 mg/dL

    High-density lipoprotein cholesterol and cognitive impairment: A U-shaped relationship in China's aging population

    PloS one

  3. High-density lipoprotein cholesterol is associated with cognitive function in humans.

    “higher HDL levels were associated with lower cognitive scores”

    Humans

    Association Between Serum Lipid Traits and Cognitive Function in Middle-aged and Elderly Adults: A Longitudinal Study

    Current Alzheimer research

  4. High-density lipoprotein cholesterol is associated with cognitive function in older adults with both hypertension and dyslipidemia (β = 0.06, P < 0.05).

    “high high-density lipoprotein cholesterol (HDL) levels resulted in higher MoCA-J scores at the follow-up (β = 0.06; P < 0.05)”

    Humansin older adults with both hypertension and dyslipidemia3-year follow-up

    Longitudinal association of hypertension and dyslipidemia with cognitive function in community-dwelling older adults: the SONIC study

    Hypertension research : official journal of the Japanese Society of Hypertension

  5. High-density lipoprotein cholesterol is associated with cognitive function in humans (rG = 0.41).

    “triglyceride (rG = 0.23) and HDLC (rG = 0.41).”

    Humans

    Genetic and environmental influences on cardiovascular risk factors and cognitive function: A Chinese twin aging study

    Geriatrics & gerontology international

Sarcopenia

upin humans5HR 1.69

5 studies
  1. High-density lipoprotein cholesterol is linked with a higher risk of sarcopenia in humans (HDL-C > 70 mg/dL) (odds ratio: 1.04 per 1 mg/dL, 95% CI, 1.00-1.08).

    “HDL-C > 70 mg/dL (n = 327) independently predicted sarcopenia (odds ratio: 1.04 per 1 mg/dL, 95% CI, 1.00-1.08).”

    HumansHDL-C > 70 mg/dLn = 327

    When 'good' cholesterol goes awry: Cross-sectional association of high HDL-C with prevalent sarcopenia in U.S. adults

    Journal of clinical lipidology

  2. Sarcopenia is associated with high-density lipoprotein cholesterol in humans (low skeletal muscle mass vs normal) (1.45 vs. 1.16 mmol/L, p < 0.001).

    “These patients had lower albumin (41.00 vs. 42.50 g/L) and lymphocyte levels (1.60 vs. 2.02 × 109/L) but higher HDL (1.45 vs. 1.16 mmol/L) and calcium levels (2.24 vs. 2.20 mmol/L) (all p < 0.001).”

    Humanslow skeletal muscle mass vs normaln = 1,002

    Development and validation of a predicative model for identifying sarcopenia in Chinese adults using nutrition indicators (AHLC)

    Frontiers in nutrition

  3. Sarcopenia is associated with high-density lipoprotein cholesterol in humans among inpatients.

    “Sarcopenia was associated with higher levels of SBP and HDL-C and lower levels of cholesterol.”

    Humansamong inpatients

    Sex differences in the association between chest computed tomography-defined sarcopenia and cardiovascular risk factors among inpatients

    Frontiers in nutrition

  4. High-density lipoprotein cholesterol is linked with a higher risk of sarcopenia in humans (compared to reference group (40-60 mg/dl)) (HR 1.69, 95% CI 1.28-2.23).

    “older adults with very high HDL-C level (>70 mg/dl) had a significantly higher risk of developing sarcopenia (HR 1.69, 95% CI 1.28-2.23)”

    Humanscompared to reference group (40-60 mg/dl)>70 mg/dlaverage 3.7-year follow-upn = 4,031

    High-density lipoprotein cholesterol level and risk of muscle strength decline and sarcopenia in older adults

    Clinical nutrition (Edinburgh, Scotland)

  5. High-density lipoprotein cholesterol is linked with a higher risk of sarcopenia in humans (OR = 1.42, 95% CI = 1.28-1.58).

    “each 1-unit increase (1 SD = 15.4 mg/dL) of HDL-C levels was associated with 42% increased odds of incident sarcopenia (OR = 1.42, 95% confidence interval [CI] = 1.28-1.58)”

    Humans4-year follow-upn = 7,415

    Association of High-Density Lipoprotein Cholesterol with Sarcopenia in Chinese Community-Dwelling Middle-Aged and Older Adults: Evidence from 4-Year Longitudinal Study

    Gerontology

More on Sarcopenia

Early age-related macular degeneration

upin humans4OR 1.187–1.25

4 studies
  1. High-density lipoprotein cholesterol is linked with a higher risk of early age-related macular degeneration in humans (OR 1.187, 95% CI 1.064-1.324).

    “Multivariable MR analysis confirmed that elevated serum HDL-C (OR = 1.187, 1.064-1.324) increased the risk of early AMD”

    Humans

    The causal effects of lifestyle, circulating, pigment, and metabolic factors on early age-related macular degeneration: a comprehensive Mendelian randomization study

    Journal of translational medicine

  2. High-density lipoprotein cholesterol is linked with a higher risk of early age-related macular degeneration in humans (two-sample Mendelian randomization) (OR 1.25, 95% CI 1.15-1.35).

    “a higher HDL-C level is strongly associated with increased risk of early AMD (OR = 1.25, 95% CI: 1.15-1.35, P = 2.61 × 10−8)”

    Humanstwo-sample Mendelian randomization

    Causal effects of serum lipid biomarkers on early age-related macular degeneration using Mendelian randomization

    Genes & nutrition

  3. High-density lipoprotein cholesterol is associated with early age-related macular degeneration in humans (controlled for age, sex, race/ethnicity, and study location) (OR per 15 mg/dL 1.16 (95% CI 1.01-1.36)).

    “early AMD was associated with a higher serum high-density lipoprotein cholesterol level (odds ratio per 15 mg/dL, 1.16; 95% confidence interval, 1.01-1.36)”

    Humanscontrolled for age, sex, race/ethnicity, and study locationn = 6,176

    Subclinical atherosclerotic cardiovascular disease and early age-related macular degeneration in a multiracial cohort: the Multiethnic Study of Atherosclerosis

    Archives of ophthalmology (Chicago, Ill. : 1960)

  4. High-density lipoprotein cholesterol raises the risk of early age-related macular degeneration in humans.

    “high-density lipoprotein cholesterol, and alcohol consumption were risk factors for early AMD incidence only”

    Review

    Global Incidence, Progression, and Risk Factors of Age-Related Macular Degeneration and Projection of Disease Statistics in 30 Years: A Modeling Study

    Gerontology

More on Early age-related macular degeneration

Cognitive impairment

upin humans2mixedin humans1downin humans1OR 2.19

3 studies
  1. High-density lipoprotein cholesterol is associated with cognitive impairment in humans (OR = 70.528, 95% CI = 3.269-1521.748).

    “reduced HDL levels were significantly linked to poor cognitive status (OR = 70.528, 95% CI = 3.269-1521.748).”

    Humansn = 236

    Prevalence of cognitive impairment and metabolic syndrome among older adults in calabar metropolis and the associated risk factors

    BMC geriatrics

  2. High-density lipoprotein cholesterol is associated with cognitive impairment in humans.

    “A U-shaped was observed between HDL-C and cognitive outcomes, individuals with higher risk in those with both low and very high HDL-C levels”

    Humans

    Very high high-density lipoprotein cholesterol may be associated with higher risk of cognitive impairment in older adults

    Nutrition journal

  3. High-density lipoprotein cholesterol is linked with a higher risk of cognitive impairment in humans (compared with HDL-C 1.50 to 1.99 mmol/L) (OR = 2.19; 95% CI, 1.12-4.28).

    “Very high HDL-C levels (≥ 2.50 mmol/L) were associated with increased risk of cognitive impairment (OR = 2.19; 95% CI, 1.12-4.28)”

    Humanscompared with HDL-C 1.50 to 1.99 mmol/L≥ 2.50 mmol/L

    Very high high-density lipoprotein cholesterol may be associated with higher risk of cognitive impairment in older adults

    Nutrition journal

  4. High-density lipoprotein cholesterol is linked with a lower risk of cognitive impairment in humans (higher HDL cholesterol levels in women).

    “In women, a higher level of high-density lipoprotein cholesterol was associated with a decreased risk of cognitive impairment.”

    Humanshigher HDL cholesterol levels in womenfemales

    Association of body mass index and blood lipid profile with cognitive function in Chinese elderly population based on data from the China Health and Nutrition Survey, 2009-2015

    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society

More on Cognitive impairment

Cardiovascular disease

upin humans2downin humans1HR 0.9–1.79

3 studies
  1. High-density lipoprotein cholesterol is linked with a higher risk of cardiovascular disease in humans (CAVI < 9) (HR 1.79, 95% CI 1.02-3.14, p = 0.044).

    “In the CAVI < 9 subgroup, low HDL-C ( < 40 mg/dL) was also associated with an increased CVEs risk (hazard ratio [HR] 1.79, 95% confidence interval [CI] 1.02-3.14, p = 0.044).”

    HumansCAVI < 9< 40 mg/dLmedian follow-up of 5.0 yearsn = 2,501

    Predictive value of high-density lipoprotein cholesterol and the cardio-ankle vascular index on cardiovascular outcomes in subjects with cardiovascular risks: the COUPLING Study

    Hypertension research : official journal of the Japanese Society of Hypertension

  2. High-density lipoprotein cholesterol is linked with a lower risk of cardiovascular disease in humans (free of CVD and cancer at baseline) (HR 0.90, 95% CI 0.84-0.97).

    “the Q6 group was associated with a lower incident CVD (HR: 0.90; 95% CI: 0.84-0.97)”

    Humansfree of CVD and cancer at baselinen = 217,442

    U-Shaped Lipid-CVD Links in Older Adults: Reversed LDL-C and HDL-C Associations and Goldilocks Zone

    JACC. Advances

  3. High-density lipoprotein cholesterol is linked with a higher risk of cardiovascular disease in humans (compared with medium-high-level group (1.55-1.80 mmol/L)) (HR 1.21 (1.06-1.38)).

    “the HR (95%CI) of CVD and all-cause mortality in low-level group were 1.21 (1.06-1.38) (P<0.05)”

    Humanscompared with medium-high-level group (1.55-1.80 mmol/L)<1.30 mmol/L

    Association between high-density lipoprotein cholesterol level and cardiovascular disease and all-cause mortality in the elderly population

    Zhonghua xin xue guan bing za zhi

More on Cardiovascular disease

Cardiovascular disease mortality

downin humans2upin humans1HR 0.443–1.24

3 studies
  1. High-density lipoprotein cholesterol is linked with a higher risk of cardiovascular disease mortality in humans (free of CVD and cancer at baseline) (HR 1.24, 95% CI 1.01-1.51).

    “and higher CVD mortality risk (HR: 1.24; 95% CI: 1.01-1.51).”

    Humansfree of CVD and cancer at baselinen = 217,442

    U-Shaped Lipid-CVD Links in Older Adults: Reversed LDL-C and HDL-C Associations and Goldilocks Zone

    JACC. Advances

  2. High-density lipoprotein cholesterol is linked with a lower risk of cardiovascular disease mortality in humans (HR=0.66, 95% CI: 0.46-0.94).

    “Similarly, the risk of cardiovascular mortality was reduced in the second tertile (HR=0.66, 95% CI: 0.46-0.94).”

    Humans37.9-45.8 mg/dL vs ≤37.9 mg/dL10 yearsn = 9,704

    Association of Serum Lipids with 10-Year CVD and All-Cause Mortality in Iranian Adults: A Prospective Cohort Study

    Archives of Iranian medicine

  3. High-density lipoprotein cholesterol is linked with a lower risk of cardiovascular disease mortality in humans after adjusting for confounders (HR = 0.443, 95% CI: 0.271-0.724).

    “HDL-C (HR = 0.443, 95% CI: 0.271-0.724) were associated with lower risk of CVD death”

    Humansafter adjusting for confoundersn = 4,499

    Cholesterol paradox in the community-living old adults: is higher better?

    Journal of geriatric cardiology : JGC

Age-related macular degeneration

upin humans3OR 1.15–1.23

3 studies
  1. High-density lipoprotein cholesterol is linked with a higher risk of age-related macular degeneration in humans (OR 1.15, 95% CI 1.04-1.28, p = 0.009).

    “high-density lipoprotein (HDL) (OR, 1.15; 95% CI, 1.04-1.28; p = 0.009) were significantly associated with early AMD”

    Humans

    The global disease burden and associated risk factors of age-related macular degeneration: a comprehensive analysis

    International ophthalmology

  2. High-density lipoprotein cholesterol is linked with a higher risk of age-related macular degeneration in AMD development.

    “MR analysis identified a protective role of TG and a risk factor role of HDL-C and CRP in AMD development.”

    Humansin AMD development

    The Impact of Blood and Urine Biomarkers on Age-Related Macular Degeneration: Insights from Mendelian Randomization and Cross-sectional Study from NHANES

    Biological procedures online

  3. High-density lipoprotein cholesterol is linked with a higher risk of age-related macular degeneration in humans (OR 1.23, p = 2.69 × 10−3).

    “there was a causal association between high-density lipoprotein-cholesterol (HDL-C) levels and an increased risk of AMD (p = 2.69 × 10−3, OR = 1.23)”

    Humans

    Causality of Diabetic Nephropathy and Age-Related Macular Degeneration: A Mendelian Randomization Study

    Gene

More on Age-related macular degeneration

Atherosclerotic cardiovascular disease

downin humans1upin humans1HR 0.85

2 studies
  1. High-density lipoprotein cholesterol is linked with a lower risk of atherosclerotic cardiovascular disease in humans (HDL-C residual added to model with apoB) (HR 0.85, 95% CI 0.84-0.87).

    “and 0.85 (95% CI: 0.84-0.87; p < 0.001) for HDL-C residual.”

    HumansHDL-C residual added to model with apoBper 1 SD10 yearsn = 293,872

    Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank

    European journal of preventive cardiology

  2. High-density lipoprotein cholesterol is associated with atherosclerotic cardiovascular disease in humans (OR = 5.61, 95% CI [2.04–15.44]).

    “There was a strong association between high-density lipoprotein (HDL) < 40 mg/dL and CVD (OR = 5.61, 95% CI [2.04–15.44] in the 70-yr group”

    Humansthree-yearn = 1,432

    Association between lipid level and atherosclerotic CVD in community-dwelling older people: the longitudinal observation of SONIC study

    Research SquarePreprint

More on Atherosclerotic cardiovascular disease

Systolic blood pressure

downin humans2

2 studies
  1. High-density lipoprotein cholesterol is associated with systolic blood pressure in humans (cross-lagged pathway analysis) (ρ=-0.651).

    “and the baseline HDL was negatively correlated with the follow-up SBP and DBP levels (ρ=-0.651, -0.505, P<0.05).”

    Humanscross-lagged pathway analysis

    Correlation study of BMI and blood pressure in Xinjiang oil workers: a cross-lagged pathway analysis with blood lipids as a mediator

    Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

  2. High-density lipoprotein cholesterol is associated with systolic blood pressure in humans (hypertension).

    “In the elderly, all three systolic blood pressure parameters are influenced by ESR and also correlate negatively with HDL”

    Humanshypertensionn = 52

    Aging and Vascular Compliance in Hypertensive Patients Mirrored in Routine Investigations

    Current health sciences journal

More on Systolic blood pressure

Progressive resistance training

mixedin humans1

1 study
  1. Progressive resistance training is associated with high-density lipoprotein cholesterol in humans.

    “HDL-C showed a significant group × time interaction, along with significant main effects of group and time.”

    Human trial16 weeksfemalesn = 32

    Effects of 16-Week Progressive Resistance Training on Arterial Stiffness and Inflammatory Markers in Older Women with and Without Metabolic Syndrome

    Artery Research

More on Progressive resistance training

Bodyweight loss

upin humans1

1 study
  1. Bodyweight loss is associated with high-density lipoprotein cholesterol in humans (tirzepatide and dulaglutide groups, changes from baseline to week 52) (r = -0.37 to -0.29, weak).

    “Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25), high-density lipoprotein cholesterol (r = -0.37 to -0.29)”

    Human trialtirzepatide and dulaglutide groups, changes from baseline to week 5252 weeks

    Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial

    Journal of diabetes investigation

Peak oxygen uptake

upin humans1

1 study
  1. Peak oxygen uptake is associated with high-density lipoprotein cholesterol in humans.

    “Changes in peak oxygen uptake were associated with changes in HDL-C in both men and women”

    Human trial5 years

    The Long-term Effect of Different Exercise Intensities on High-Density Lipoprotein Cholesterol in Older Men and Women Using the Per Protocol Approach: The Generation 100 Study

    Mayo Clinic proceedings. Innovations, quality & outcomes

Adiponectin

upin humans1

1 study
  1. Adiponectin is associated with high-density lipoprotein cholesterol in humans after 3 months of exercise cessation.

    “Adiponectin was positively correlated with high-density lipoprotein”

    Human trialafter 3 months of exercise cessation3 monthsn = 49

    Exercise cessation in active older adults: Effects on inflammatory markers and adiponectin

    Geriatrics & gerontology international

More on Adiponectin

All 78

Latest

Dec 2025: 40Jan 2026: 96Feb 2026: 109Mar 2026: 91Apr 2026: 24May 2026: 17Jun 2026: 39Jul 2026: 54Aug 2026: 65Sep 2026: 71Oct 2026: 84Nov 2026: 41731 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Clinical obesity has genetic links beyond body mass index

Of 127 genetic regions linked to clinical obesity, 63 had no significant link to body mass index in an analysis across five ancestry groups.Of 127 genetic regions linked to clinical obesity, 63 had no significant link to body mass index in an analysis across five ancestry groups.

Genetic association studyMechanisms
AHA Scientific Sessions 2026 Abstract

Orforglipron increased metabolic syndrome resolution in trials

At 36 milligrams, resolution after 72 weeks reached 62.8% versus 35.5% with placebo in ATTAIN-1 and 52.8% versus 15.1% in ATTAIN-2 among participants with metabolic…At 36 milligrams, resolution after 72 weeks reached 62.8% versus 35.5% with placebo in ATTAIN-1 and 52.8% versus 15.1% in ATTAIN-2 among participants with metabolic syndrome at baseline.

Randomized trialOrforglipron

See all 1,846 papers on high-density lipoprotein cholesterol